Thiomersal free trivalent influenza split vaccine 2003/2004
Biological2 doses, intramuscular injection
NCT Number: NCT00731393
The aim of the present study is to assess the reactogenicity and immunogenicity of a thiomersal-free influenza vaccine. For comparison, a group of subjects is administered the standard formulation of Influsplit SSW® 2003/2004.
Looking for future studies?
Notify Me6 month–6 year
All sexes
Interventional
Phase 3
GSK Investigational Site, Bützow, Mecklenburg-Vorpommern, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 doses, intramuscular injection
2 doses, intramuscular injection
Other names: Thiomersal free trivalent influenza split vaccine 2003/2004
Time frame: On Day 21 (+- 2) after the second vaccination
Time frame: Within 4 days after each vaccination
Time frame: Within 30 days after each vaccination
Time frame: Throughout the study
Time frame: On Day 21 (+- 2), Month 3 and Month 6 after the second vaccination
GlaxoSmithKline
Industry
To Determine the Immunogenicity and Reactogenicity of a Thiomersal Free Trivalent Influenza Split Vaccine 2003/2004 or of GSK Biologicals' Standard Formulation Influsplit SSW®/Fluarix™ 2003/2004 in Children Aged From 6 Months Until 6 Years
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsNCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details